Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsIONTOPHORESISGeneric

ZECUITY

SUMATRIPTAN SUCCINATE

Standard Dose
EQ 6.5MG BASE/4HR
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview ZECUITY is listed in Drugs@FDA under application 202278 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient SUMATRIPTAN SUCCINATE Form and strength SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR Sponsor TEVA BRANDED PHARM Submission history Latest submission status date: 2015-08-24 00:00:00.

Structured Monograph

Clinical summary

Approval overview ZECUITY is listed in Drugs@FDA under application 202278 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient SUMATRIPTAN SUCCINATE Form and strength SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR Sponsor TEVA BRANDED PHARM Submission history Latest submission status date: 2015-08-24 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
ZECUITY (SUMATRIPTAN SUCCINATE) | Drug Monograph | MedicHelpline